Profile data is unavailable for this security.
About the company
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
- Revenue in USD (TTM)0.00
- Net income in USD-67.28m
- Incorporated2013
- Employees7.00
- LocationPortage Biotech IncClarence Thomas Building, Road TownP.O. Box 4649TORTOLA VG1110Virgin Islands (British)VGB
- Phone+1 4 169291806
- Fax+1 4 169296612
- Websitehttps://portagebiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibio Inc | 375.00k | -16.46m | 13.46m | 16.00 | -- | 0.7205 | -- | 35.88 | -1.81 | -2.34 | 0.0414 | 1.13 | 0.0108 | -- | -- | 23,437.50 | -47.53 | -27.69 | -77.58 | -33.13 | -- | -- | -4,389.33 | -1,862.11 | -- | -- | 0.0855 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| Cell Source Inc | 0.00 | -6.57m | 13.52m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -69.40m | 13.67m | 52.00 | -- | 0.656 | -- | -- | -1.71 | -1.71 | 0.00 | 0.5029 | 0.00 | -- | -- | 0.00 | -149.01 | -79.03 | -202.35 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Lyra Therapeutics Inc | 1.19m | -79.53m | 13.82m | 30.00 | -- | 2.94 | -- | 11.66 | -60.71 | -60.71 | 0.9039 | 2.94 | 0.012 | -- | -- | 39,500.00 | -80.40 | -64.59 | -94.88 | -76.36 | -- | -- | -6,711.39 | -5,844.58 | -- | -- | 0.00 | -- | -1.54 | -- | -49.07 | -- | 61.78 | -- |
| MetaVia Inc | 0.00 | -24.55m | 14.07m | 9.00 | -- | 1.42 | -- | -- | -3.27 | -3.27 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -168.46 | -99.54 | -336.06 | -140.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -121.27 | -- | -48.18 | -- |
| Portage Biotech Inc | 0.00 | -67.28m | 14.10m | 7.00 | -- | 4.94 | -- | -- | -64.27 | -64.27 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -141.56 | -30.53 | -145.61 | -40.02 | -- | -- | -- | -- | -- | -- | 0.0387 | -- | -- | -- | 27.98 | -- | -- | -- |
| Synlogic Inc | 0.00 | 2.56m | 14.16m | 1.00 | 5.44 | 1.08 | 5.52 | -- | 0.2226 | 0.2226 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | 9.49 | -44.41 | 13.42 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Bullfrog AI Holdings Inc | 0.00 | -7.14m | 14.22m | 9.00 | -- | 4.38 | -- | -- | -0.8102 | -0.8102 | 0.00 | 0.3448 | 0.00 | -- | -- | 0.00 | -121.13 | -- | -141.43 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -100.00 | -- | -31.42 | -- | -- | -- |
| Ernexa Therapeutics Inc | 535.00k | -46.11m | 14.35m | 6.00 | -- | -- | -- | 26.83 | -93.67 | -93.67 | 0.313 | -1.71 | 0.0196 | -- | 2.11 | 89,166.66 | -168.48 | -187.10 | -252.50 | -237.72 | 93.46 | -- | -8,615.70 | -3,375.91 | -- | -2.31 | -- | -- | 755.88 | -50.61 | -105.47 | -- | -19.54 | -- |
| Neuphoria Therapeutics Inc | -100.00bn | -100.00bn | 14.46m | 8.00 | -- | 0.5484 | -- | -- | -- | -- | -- | 14.02 | -- | -- | -- | -- | -- | -36.91 | -- | -41.62 | -- | -- | -- | -28,341.54 | -- | -- | 0.0012 | -- | -- | -- | 27.54 | -- | -- | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 14.51m | 82.00 | -- | 0.4215 | -- | 1.55 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| Edesa Biotech Inc | 0.00 | -5.84m | 14.68m | 16.00 | -- | 2.31 | -- | -- | -1.60 | -1.60 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -50.92 | -102.42 | -58.78 | -121.94 | -- | -- | -- | -15,754.49 | -- | -- | 0.00 | -- | -- | -- | 26.32 | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 1.53m | -17.61m | 14.68m | 12.00 | -- | -- | -- | 9.62 | -163.19 | -163.19 | 14.47 | -494.90 | 0.0934 | -- | 34.73 | -- | -107.82 | -56.28 | -328.40 | -73.72 | -- | -- | -1,154.22 | -528.18 | -- | -- | -- | -- | 10,183.69 | 87.68 | -30.85 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 14.72m | 0.00 | -- | -- | -- | -- | -0.0736 | -0.0736 | 0.00 | -0.0374 | 0.00 | -- | -- | -- | -626.91 | -- | -- | -- | -- | -- | -- | -- | -- | -126.09 | -- | -- | -- | -- | -13.02 | -- | -- | -- |
Data as of Jul 11 2025. Currency figures normalised to Portage Biotech Inc's reporting currency: US Dollar USD
2.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| QTR Family Wealth, LLCas of 31 Mar 2025 | 19.27k | 1.72% |
| UBS Securities LLCas of 31 Mar 2025 | 10.21k | 0.91% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2025 | 504.00 | 0.05% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 348.00 | 0.03% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2025 | 125.00 | 0.01% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2025 | 79.00 | 0.01% |
| National Bank Financial, Inc.as of 31 Mar 2025 | 73.00 | 0.01% |
| CA Indosuez (Switzerland) SAas of 31 Mar 2025 | 68.00 | 0.01% |
| BlackRock Financial Management, Inc.as of 31 Mar 2025 | 60.00 | 0.01% |
| Osaic Advisory Services LLCas of 31 Mar 2025 | 50.00 | 0.00% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
